SG10201911695SA - Improved polyethyleneimine polyethyleneglycol vectors - Google Patents
Improved polyethyleneimine polyethyleneglycol vectorsInfo
- Publication number
- SG10201911695SA SG10201911695SA SG10201911695SA SG10201911695SA SG10201911695SA SG 10201911695S A SG10201911695S A SG 10201911695SA SG 10201911695S A SG10201911695S A SG 10201911695SA SG 10201911695S A SG10201911695S A SG 10201911695SA SG 10201911695S A SG10201911695S A SG 10201911695SA
- Authority
- SG
- Singapore
- Prior art keywords
- vectors
- improved
- polyethyleneglycol
- polyethyleneimine
- polyethyleneimine polyethyleneglycol
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 229920002873 Polyethylenimine Polymers 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993110P | 2014-05-14 | 2014-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911695SA true SG10201911695SA (en) | 2020-01-30 |
Family
ID=54479412
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609442YA SG11201609442YA (en) | 2014-05-14 | 2015-05-14 | Improved polyethyleneimine polyethyleneglycol vectors |
| SG10201911695SA SG10201911695SA (en) | 2014-05-14 | 2015-05-14 | Improved polyethyleneimine polyethyleneglycol vectors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609442YA SG11201609442YA (en) | 2014-05-14 | 2015-05-14 | Improved polyethyleneimine polyethyleneglycol vectors |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10278991B2 (en) |
| EP (1) | EP3142673A4 (en) |
| JP (3) | JP6753843B2 (en) |
| KR (2) | KR102589295B1 (en) |
| CN (3) | CN106687121A (en) |
| AU (2) | AU2015260725B2 (en) |
| BR (1) | BR112016026581A2 (en) |
| CA (1) | CA2949017A1 (en) |
| IL (2) | IL287206B2 (en) |
| MA (1) | MA39970A (en) |
| MX (2) | MX2016014881A (en) |
| NZ (1) | NZ727092A (en) |
| PH (1) | PH12016502258A1 (en) |
| RU (1) | RU2771104C2 (en) |
| SG (2) | SG11201609442YA (en) |
| WO (1) | WO2015173824A1 (en) |
| ZA (1) | ZA201608042B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201609442YA (en) * | 2014-05-14 | 2016-12-29 | Alex Levitzki Man And Holdings Ltd | Improved polyethyleneimine polyethyleneglycol vectors |
| SG10202110138TA (en) | 2015-11-17 | 2021-10-28 | Highlight Therapeutics S L | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| CN109071419A (en) * | 2016-03-07 | 2018-12-21 | 韩美药品株式会社 | Polyethyleneglycol derivative and application thereof |
| WO2018042411A1 (en) * | 2016-09-04 | 2018-03-08 | Alex Levitzki Management And Holdings, Ltd. | Chimeric proteins for targeting dsrna |
| EP4122449A1 (en) | 2017-05-17 | 2023-01-25 | Highlight Therapeutics, S.L. | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| IL273195B2 (en) * | 2017-09-27 | 2024-04-01 | Targimmune Therapeutics Ag | Castration resistant prostate cancer |
| WO2019170890A1 (en) * | 2018-03-08 | 2019-09-12 | Targimmune Therapeutics Ag | A recombinant protein comprising a double stranded rna binding domain |
| CN109893657B (en) * | 2019-02-28 | 2022-04-29 | 中国人民解放军军事科学院军事医学研究院 | Gene delivery carrier, drug compound, anti-pulmonary fibrosis drug and application |
| KR20210146952A (en) * | 2019-04-03 | 2021-12-06 | 타르그이뮨 테라퓨틱스 아게 | Immunotherapy for the treatment of cancer |
| WO2020263782A1 (en) * | 2019-06-24 | 2020-12-30 | North Carolina State University | Methods and compositions for modifying nucleic acids and for killing cells |
| WO2021001023A1 (en) * | 2019-07-02 | 2021-01-07 | Biontech Rna Pharmaceuticals Gmbh | Rna formulations suitable for therapy |
| CA3192963A1 (en) | 2020-10-08 | 2022-04-14 | Esteban Pombo-Villar | Immunotherapy for the treatment of cancer |
| WO2023079142A2 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
| US20240091348A1 (en) * | 2022-09-20 | 2024-03-21 | Highlight Therapeutics, S.L. | Novel compositions based on polyinosinic-polycytidylic acid |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0532525T3 (en) | 1990-05-18 | 1995-12-04 | Genentech Inc | Novel protein-polycation conjugates |
| DE4104186A1 (en) | 1991-02-12 | 1992-08-13 | Genentech Inc | NEW COMPLEXES INCLUDING ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID |
| IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| DE19726186A1 (en) | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Complexes for the transport of nucleic acid into higher eukaryotic cells |
| US6545138B1 (en) | 1998-05-25 | 2003-04-08 | Nippon Shinyaku Co., Ltd. | Process for producing composite preparation containing nucleic acid |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| US20040043030A1 (en) | 2001-07-31 | 2004-03-04 | Immunomedics, Inc. | Polymeric delivery systems |
| GB0119346D0 (en) | 2001-08-08 | 2001-10-03 | Bioclones Proprietary Ltd | Process for the maturation of dendritic cells |
| US20040105839A1 (en) | 2001-11-28 | 2004-06-03 | Myung-Ok Park | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| AU2002236324A1 (en) | 2002-02-28 | 2003-09-09 | Jong Sang Park | Cationic highly branched polyaminoester |
| US20060211637A1 (en) | 2002-08-06 | 2006-09-21 | Intradigm Corporation | Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| JP2006506433A (en) | 2002-11-18 | 2006-02-23 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | Targeted double-stranded RNA-mediated cell killing |
| US8969543B2 (en) | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
| AU2003219576A1 (en) | 2003-04-03 | 2004-10-25 | Korea Advanced Institute Of Science And Technology | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
| US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US20050118718A1 (en) | 2003-09-22 | 2005-06-02 | University Of Utah Research Foundation | Stabilization and controlled delivery of ionic biopharmaceuticals |
| US20050277575A1 (en) | 2004-03-24 | 2005-12-15 | Alexandre Semov | Therapeutic compositions and methods for treating diseases that involve angiogenesis |
| WO2006054129A1 (en) | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| US7893244B2 (en) | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
| CN101287500A (en) * | 2005-08-19 | 2008-10-15 | 恩多塞特公司 | Multi-drug ligand conjugates |
| US20090011004A1 (en) | 2005-12-30 | 2009-01-08 | Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
| US20070231392A1 (en) | 2006-01-23 | 2007-10-04 | Ernst Wagner | CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY |
| US20070225213A1 (en) | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
| EP2007435B1 (en) | 2006-03-31 | 2019-12-18 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| AU2008289108B2 (en) | 2007-08-17 | 2014-09-18 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| HUE035101T2 (en) | 2007-09-28 | 2018-05-02 | Pfizer | Cancer Cell Targeting Using Nanoparticles |
| CN105770878A (en) | 2007-10-12 | 2016-07-20 | 麻省理工学院 | Vaccine Nanotechnology |
| US20110027172A1 (en) | 2007-12-10 | 2011-02-03 | Zhuang Wang | Drug delivery system for pharmaceuticals and radiation |
| US20110038888A1 (en) | 2008-01-10 | 2011-02-17 | Peter Emtage | Adjuvant compositions comprising poly-ic and a cationic polymer |
| WO2009131435A1 (en) | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
| EP2113257A1 (en) | 2008-04-30 | 2009-11-04 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer |
| EP2123304A1 (en) | 2008-05-23 | 2009-11-25 | Freie Universität Berlin | Compounds suited as nanocarriers for active agents and their use |
| WO2009151539A1 (en) | 2008-05-24 | 2009-12-17 | Sirnaomics, Inc. | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS |
| JP2011525180A (en) | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | Method for the manufacture of targeted drugs functionalized with diblock copolymers for use in the production of therapeutically targeted nanoparticles |
| SI3098239T1 (en) * | 2008-12-22 | 2020-03-31 | Targimmune Therapeutics Ag | Egfr-homing double-stranded rna vector for systemic cancer treatment |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| US20100266642A1 (en) | 2009-02-20 | 2010-10-21 | Bind Biosciences, Inc. | Modified cells for targeted cell trafficking and uses thereof |
| ES2588183T3 (en) | 2009-03-31 | 2016-10-31 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Procedure for the prevention of influenza using a vaccine for intranasal administration |
| WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
| ES2368963B1 (en) | 2009-07-04 | 2012-10-10 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | PROCEDURE FOR IDENTIFICATION OF THERAPEUTIC AGENTS AGAINST MELANOMA AND USE OF IDENTIFIED AGENT. |
| CN101638484A (en) * | 2009-08-24 | 2010-02-03 | 中国科学院长春应用化学研究所 | Polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, preparation method thereof and application thereof |
| AU2010328136B2 (en) | 2009-12-09 | 2016-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
| ES2780156T3 (en) | 2009-12-15 | 2020-08-24 | Pfizer | Therapeutic compositions of polymeric nanoparticles with high glass transition temperature or high molecular weight copolymers |
| JP5898627B2 (en) | 2009-12-15 | 2016-04-06 | バインド セラピューティックス インコーポレイテッド | Therapeutic polymer nanoparticles containing epothilone and methods of making and using the same |
| EA201290497A1 (en) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | THERAPEUTIC POLYMERIC NANOPARTICLES, INCLUDING CORTICOSTEROIDS, AND METHODS OF OBTAINING SUCH |
| CA2788600C (en) | 2010-02-24 | 2019-12-03 | Arrowhead Research Corporation | Compositions for targeted delivery of sirna |
| WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
| US20110256227A1 (en) | 2010-04-14 | 2011-10-20 | Intezyne Technologies, Inc. | Controlled polyplex assembly |
| EP2395041A1 (en) | 2010-06-10 | 2011-12-14 | F. Hoffmann-La Roche AG | Polymers for delivery of nucleic acids |
| WO2011154331A1 (en) | 2010-06-10 | 2011-12-15 | F. Hoffmann-La Roche Ag | Polymers for delivery of nucleic acids |
| NZ605420A (en) | 2010-07-06 | 2015-02-27 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| US20120207795A1 (en) | 2010-07-13 | 2012-08-16 | The Regents Of The University Of California | Cationic polymer coated mesoporous silica nanoparticles and uses thereof |
| FR2963350B1 (en) | 2010-07-30 | 2013-11-01 | Univ D Evry Val D Essonne | NOVEL BLOCK COPOLYMERS AND THEIR USES FOR DELIVERING AN ACTIVE SUBSTANCE INTO A CELL. |
| WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| US8461224B2 (en) | 2011-03-04 | 2013-06-11 | National Health Research Institutes | Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery |
| US10029023B2 (en) | 2011-03-31 | 2018-07-24 | The Johns Hopkins University | Theranostic imaging agents and methods of use |
| WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
| MX2014013367A (en) | 2012-05-02 | 2014-12-08 | Novartis Ag | Organic compositions to treat kras-related diseases. |
| PL2852668T3 (en) | 2012-07-12 | 2016-11-30 | Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell | |
| CA2912975A1 (en) | 2012-10-16 | 2014-04-24 | William Marsh Rice University | An improved nanovector based drug delivery system for overcoming drug resistance |
| US10201556B2 (en) | 2012-11-06 | 2019-02-12 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway |
| EA201890915A1 (en) | 2012-11-15 | 2018-09-28 | Эндосайт, Инк. | CONJUGATES FOR DELIVERY OF MEDICINES AND METHODS OF TREATMENT OF DISEASES CAUSED BY CELLS EXPRESSING PSMA |
| EP2930180B1 (en) | 2012-12-06 | 2021-11-10 | Kyowa Hakko Bio Co., Ltd. | Double-stranded ribonucleic acid for adjuvants |
| DK3013964T3 (en) | 2013-06-28 | 2020-06-15 | Ethris Gmbh | COMPOSITIONS FOR INTRODUCING RNA IN CELLS |
| CN104341488A (en) | 2013-08-02 | 2015-02-11 | 复旦大学 | c(LyP-1) polypeptide and nano-delivery system constructed thereby and application of nano-delivery system |
| US20160312218A1 (en) | 2013-11-04 | 2016-10-27 | Northeastern University | System for co-delivery of polynucleotides and drugs into protease-expressing cells |
| JP2017505104A (en) | 2013-11-08 | 2017-02-16 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Nucleic acid nanostructures for in vivo drug delivery |
| SI3116547T1 (en) | 2014-03-14 | 2019-08-30 | Pfizer, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| US10273484B2 (en) | 2014-03-24 | 2019-04-30 | Riboxx Gmbh | Double-stranded RNA conjugates and their use |
| CN107073090A (en) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | With reference to vaccine device and kill cancer cell method |
| SG11201609442YA (en) * | 2014-05-14 | 2016-12-29 | Alex Levitzki Man And Holdings Ltd | Improved polyethyleneimine polyethyleneglycol vectors |
| AU2016214978B2 (en) | 2015-02-05 | 2021-12-09 | The University Of Queensland | Targeting constructs for delivery of payloads |
| WO2016183447A1 (en) | 2015-05-14 | 2016-11-17 | The Johns Hopkins University | Compositions of nucleic acid-containing nanoparticles for in vivo delivery |
| SG10202110138TA (en) | 2015-11-17 | 2021-10-28 | Highlight Therapeutics S L | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
-
2015
- 2015-05-14 SG SG11201609442YA patent/SG11201609442YA/en unknown
- 2015-05-14 CN CN201580025099.3A patent/CN106687121A/en active Pending
- 2015-05-14 NZ NZ727092A patent/NZ727092A/en unknown
- 2015-05-14 IL IL287206A patent/IL287206B2/en unknown
- 2015-05-14 BR BR112016026581A patent/BR112016026581A2/en active Search and Examination
- 2015-05-14 KR KR1020227041535A patent/KR102589295B1/en active IP Right Grant
- 2015-05-14 CA CA2949017A patent/CA2949017A1/en active Pending
- 2015-05-14 US US15/310,735 patent/US10278991B2/en active Active
- 2015-05-14 SG SG10201911695SA patent/SG10201911695SA/en unknown
- 2015-05-14 CN CN202310954498.4A patent/CN116966310A/en active Pending
- 2015-05-14 KR KR1020167033997A patent/KR102472590B1/en active IP Right Grant
- 2015-05-14 WO PCT/IL2015/050514 patent/WO2015173824A1/en active Application Filing
- 2015-05-14 MA MA039970A patent/MA39970A/en unknown
- 2015-05-14 MX MX2016014881A patent/MX2016014881A/en active IP Right Grant
- 2015-05-14 EP EP15793532.1A patent/EP3142673A4/en active Pending
- 2015-05-14 RU RU2016146389A patent/RU2771104C2/en active
- 2015-05-14 CN CN202310955550.8A patent/CN116966311A/en active Pending
- 2015-05-14 AU AU2015260725A patent/AU2015260725B2/en active Active
- 2015-05-14 JP JP2017512466A patent/JP6753843B2/en active Active
-
2016
- 2016-11-10 IL IL248890A patent/IL248890B/en unknown
- 2016-11-11 PH PH12016502258A patent/PH12016502258A1/en unknown
- 2016-11-14 MX MX2020012698A patent/MX2020012698A/en unknown
- 2016-11-21 ZA ZA2016/08042A patent/ZA201608042B/en unknown
-
2019
- 2019-03-07 US US16/296,117 patent/US11298376B2/en active Active
- 2019-03-08 US US16/297,133 patent/US10543232B2/en active Active
-
2020
- 2020-08-20 JP JP2020139643A patent/JP7406475B2/en active Active
-
2021
- 2021-05-24 AU AU2021203336A patent/AU2021203336A1/en active Pending
-
2022
- 2022-03-02 US US17/653,221 patent/US20220339189A1/en active Pending
-
2023
- 2023-12-15 JP JP2023211790A patent/JP2024028995A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287206A (en) | Improved polyethyleneimine polyethyleneglycol vectors | |
| GB201715843D0 (en) | No details | |
| GB2549809C (en) | Vector | |
| SI3145949T1 (en) | Lentiviral vectors | |
| GB201403684D0 (en) | Vector | |
| GB201715887D0 (en) | No details | |
| GB201622033D0 (en) | No details | |
| GB201714253D0 (en) | No details | |
| GB201411344D0 (en) | Cloning | |
| GB201412494D0 (en) | Vector production | |
| GB201509578D0 (en) | Vectors | |
| GB201614093D0 (en) | Vector | |
| GB201702043D0 (en) | No details | |
| GB201709809D0 (en) | No details | |
| GB201703185D0 (en) | No details | |
| IL247535A0 (en) | Poxviral oncolytic vectors | |
| RS59406B1 (en) | Improved biobinder | |
| GB201509881D0 (en) | Complementary vectors | |
| GB201419801D0 (en) | Antennas | |
| GB201402083D0 (en) | Retaining means | |
| GB201709361D0 (en) | No details | |
| GB201709806D0 (en) | No details | |
| GB201711661D0 (en) | No details | |
| GB201710661D0 (en) | No details | |
| GB201714201D0 (en) | No details |